Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Opioid-receptor agonist antidiarrheal agent (peripherally acting)

Loperamide

Imodium

Dosage form
Tablet
Available strengths
2 mg (orally disintegrating tablet); 2 mg/15 mL (oral solution); 2 mg (capsule)
Drug class
Opioid-receptor agonist antidiarrheal agent (peripherally acting)
Common brand
Imodium

Clinical overview. Loperamide (Imodium) is an over-the-counter antidiarrheal medicine that slows down an overactive gut to relieve acute and chronic diarrhea, including diarrhea related to inflammatory bowel disease or bowel surgery. It comes in fast-dissolving tablets, capsules, and an oral liquid, and is generally well tolerated with constipation as the most common side effect. Taking more than the recommended amount can cause serious, sometimes fatal, heart rhythm problems, so the maximum daily dose should never be exceeded.

Indication

Common therapeutic uses

  • Loperamide is used as an add-on to rehydration therapy for the short-term relief of sudden, non-specific diarrhea.
  • Loperamide is used for chronic diarrhea associated with inflammatory bowel disease.
  • Loperamide is used to reduce the volume of discharge in people with ileostomies, colostomies, or other bowel resections.

Pregnancy

Risk assessment and monitoring considerations

  • The safety of loperamide during pregnancy has not been established, so it should be used in pregnant women only if the potential benefit outweighs the potential risk, particularly in the first trimester.
  • Animal studies at doses far higher than the human dose did not show harm to the fetus or impaired fertility.

Breastfeeding

Infant exposure considerations

  • Small amounts of loperamide may pass into breast milk, so breastfeeding is not recommended while taking loperamide.

Geriatrics

Dosing and tolerability considerations

  • No dose adjustment is required for adults over 65 years of age.

Pediatrics

Use in children and adolescents

  • Loperamide is contraindicated in children under 2 years of age.
  • Loperamide should be used in children only on the advice of a physician.
  • The orally disintegrating tablet and capsule forms are not suitable for children under 6 years of age.
  • The oral solution is intended for use in adults and children 12 years of age and older only.

Dosage & Administration

Practical dosing and administration

  • For acute diarrhea in adults and children 12 years and older, an initial dose is taken first, followed by a smaller dose after each subsequent loose stool, up to a stated maximum daily amount; treatment should stop once stools become normal or if no bowel movement occurs for 24 hours.
  • For chronic diarrhea, an initial dose is taken, followed by a smaller dose after each unformed stool until diarrhea is controlled, after which the dose is reduced to the lowest amount that maintains control.
  • If no improvement occurs after 10 days of maximum-dose treatment, further treatment is unlikely to help and a physician should be consulted.
  • For children aged 6 to 12 years, dosing is weight-based and should only be started on a physician's advice.
  • No dose adjustment is needed for kidney impairment.
  • Loperamide should be used with caution in patients with liver impairment because reduced first-pass metabolism can lead to a relative overdose.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose can cause central nervous system depression, including stupor, poor coordination, drowsiness, pinpoint pupils, and muscle stiffness.
  • Overdose can cause slowed or difficult breathing (respiratory depression).
  • Urinary retention and bowel blockage (ileus) may occur with overdose.
  • Children may be more sensitive to the central nervous system effects of overdose than adults.
  • Large intentional overdoses have been linked to heart rhythm disturbances, including QT prolongation and serious ventricular arrhythmias, and can unmask an inherited heart rhythm condition called Brugada syndrome.
  • Activated charcoal given soon after ingestion can reduce absorption of the drug; naloxone may be used to reverse central nervous system symptoms, with repeated doses and prolonged monitoring since loperamide lasts longer than naloxone.

Common side effects

Frequently reported tolerability concerns

  • Abdominal pain or discomfort may occur.
  • Drowsiness or dizziness may occur.
  • Tiredness may occur.
  • Dry mouth may occur.
  • Nausea and vomiting may occur.
  • Constipation may occur.
  • Flatulence may occur.
  • A burning or prickling feeling on the tongue may occur with the orally disintegrating tablet immediately after use.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Severe allergic reactions, including anaphylaxis and severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, may rarely occur.
  • Bowel blockage (ileus), including toxic megacolon, may occur, especially if the recommended dose or treatment duration is exceeded.
  • Abdominal swelling or distension may occur and is a sign to stop the medicine and seek medical advice.
  • Loss of consciousness or a depressed level of consciousness may occur, particularly with overdose or in young children.
  • Urinary retention may occur.
  • Heart rhythm disturbances, including QT prolongation and serious ventricular arrhythmias, have been reported, mainly with misuse or overdose.
  • Seek immediate medical help for abdominal swelling, severe constipation, signs of an allergic reaction, fainting, or an irregular heartbeat.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with liver impairment, since reduced first-pass metabolism raises the risk of central nervous system toxicity.
  • Use with caution in young children and in anyone with a compromised blood-brain barrier, such as from meningitis, because of greater variability in response.
  • Use with caution in patients with dehydration, particularly young children, since this can further affect how the body responds to loperamide.
  • Use with caution in patients with HIV-associated infectious colitis, and stop the medicine at the earliest signs of abdominal distension.
  • Use with caution when driving or operating machinery, since tiredness, dizziness, or drowsiness can occur with diarrheal illness treated with loperamide.
  • Use with caution in anyone with a history of opioid misuse, since loperamide has been misused as an opioid substitute at high doses.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients hypersensitive to loperamide or to any ingredient in the formulation.
  • Contraindicated in children under 2 years of age.
  • Contraindicated in patients in whom constipation must be avoided.
  • Contraindicated in acute dysentery, which involves blood in the stool and fever.
  • Contraindicated in acute ulcerative colitis.
  • Contraindicated in bacterial enterocolitis caused by invasive organisms such as Salmonella, Shigella, and Campylobacter.
  • Contraindicated in pseudomembranous colitis associated with broad-spectrum antibiotic use.
  • Loperamide must be stopped promptly if abdominal distension or other unexpected symptoms develop.

Drug interactions

Clinically relevant combinations

  • Combining loperamide with quinidine or ritonavir, which block the P-glycoprotein transporter, can significantly raise loperamide blood levels.
  • Combining loperamide with itraconazole or ketoconazole, which inhibit CYP3A4 and P-glycoprotein, can significantly raise loperamide blood levels.
  • Gemfibrozil can increase loperamide blood levels, and the effect is greater when combined with itraconazole.
  • Loperamide can increase blood levels of oral desmopressin by slowing gastrointestinal motility.
  • Other medicines that slow the gut, such as certain antidepressants and some cold or allergy medicines, may increase the effect of loperamide.
  • Sedating medications may add to the drowsiness caused by loperamide.

Food interactions

Meal-related administration

  • Loperamide can be taken with or without food; no specific food-related dosing restriction applies.
  • When treating diarrhea, avoid alcohol, milk, and fatty, spicy, or high-fibre foods, as these can worsen diarrhea symptoms.

Time of administration

Practical scheduling

  • Loperamide can be taken at any time of day, with or without food, following each loose stool as directed, up to the maximum daily amount.

Storage

Product handling

  • Store the orally disintegrating tablets and capsules at room temperature (15°C to 30°C), protected from moisture.
  • Store the oral solution at room temperature (15°C to 30°C), protected from light.

Patient take-away

Key counselling points for a quick closing summary

  • Loperamide is not a cure for diarrhea; whenever possible, the underlying cause should also be treated.
  • Drink plenty of clear fluids while taking loperamide, since diarrhea can cause significant fluid loss.
  • Stop taking loperamide and see a doctor if diarrhea lasts more than 48 hours, if you develop a high fever or blood in the stool, or if your abdomen becomes swollen or painful.
  • Do not exceed the maximum daily dose, since higher-than-recommended doses have been linked to serious, sometimes fatal, heart problems.

References

Source material and product information

  1. Health Canada Product Monograph — Loperamide

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.